15–16 June 2026 | Berlin, Germany
Drug Discovery Europe 2026 unites over 800 senior pharma, biotech, and AI leaders to accelerate the journey from target to clinical candidate.
Keynote highlights include Paul Workman OBE FRS (Institute of Cancer Research, London) on precision medicine for cancer, Rafal Kaminski (Angelini Pharma) on global brain health, Dave Hallett (Recursion) on the 2026 AI landscape, and Ingo Hartung (Merck Healthcare KGaA) on designing beyond inhibitors.
